X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (51) 51
hematology (42) 42
male (39) 39
female (37) 37
index medicus (35) 35
middle aged (35) 35
aged (29) 29
adult (27) 27
treatment outcome (24) 24
multiple myeloma (22) 22
oncology (22) 22
multiple myeloma - drug therapy (20) 20
multiple myeloma - mortality (18) 18
multiple myeloma - therapy (18) 18
bortezomib (16) 16
therapy (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
disease-free survival (13) 13
transplantation (12) 12
transplantation, homologous (12) 12
stem-cell transplantation (11) 11
elderly-patients (10) 10
hematopoietic stem cell transplantation (10) 10
retrospective studies (10) 10
thalidomide - administration & dosage (10) 10
thalidomide - analogs & derivatives (10) 10
hematology, oncology and palliative medicine (9) 9
recurrence (9) 9
survival analysis (9) 9
thalidomide (9) 9
transplantation, autologous (9) 9
dexamethasone (8) 8
multiple myeloma - pathology (8) 8
stem cells (8) 8
survival (8) 8
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
boronic acids - administration & dosage (7) 7
diagnosis (7) 7
lenalidomide (7) 7
melphalan (7) 7
pyrazines - administration & dosage (7) 7
risk factors (7) 7
abridged index medicus (6) 6
adolescent (6) 6
chemotherapy (6) 6
chronic myelogenous leukemia (6) 6
dexamethasone - administration & dosage (6) 6
follow-up studies (6) 6
immunology (6) 6
multiple myeloma - complications (6) 6
multiple myeloma - diagnosis (6) 6
prognosis (6) 6
risk (6) 6
stem cell transplantation (6) 6
boronic acids - adverse effects (5) 5
bortezomib-melphalan-prednisone (5) 5
care and treatment (5) 5
chronic myeloid-leukemia (5) 5
graft vs host disease - immunology (5) 5
hematopoietic stem cells (5) 5
kaplan-meier estimate (5) 5
lymphoma (5) 5
melphalan - administration & dosage (5) 5
myeloma (5) 5
prednisone - administration & dosage (5) 5
prednisone plus thalidomide (5) 5
pyrazines - adverse effects (5) 5
relapse (5) 5
remission induction (5) 5
salvage therapy (5) 5
thalidomide - adverse effects (5) 5
thalidomide - therapeutic use (5) 5
time factors (5) 5
unrelated donors (5) 5
versus-host-disease (5) 5
allogeneic stem cell transplantation (4) 4
autologous transplantation (4) 4
blood (4) 4
bone marrow (4) 4
bone marrow transplantation (4) 4
bone-marrow transplantation (4) 4
cancer (4) 4
carfilzomib (4) 4
criteria (4) 4
disease progression (4) 4
drug therapy (4) 4
fusion proteins, bcr-abl - genetics (4) 4
hematopoietic stem cell transplantation - methods (4) 4
initial treatment (4) 4
italy (4) 4
management (4) 4
minimal residual disease (4) 4
multiple myeloma - immunology (4) 4
multiple-myeloma (4) 4
patient outcomes (4) 4
plus dexamethasone (4) 4
prednisone (4) 4
prognostic-factors (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2017, Volume 17, Issue 1, pp. e46 - e46
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3240 - 3240
Abstract INTRODUCTION: High-risk cytogenetic abnormalities, such as del(17p), t(4;14), and/or t(14;16), are associated to an unfavorable prognosis. Several... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 7/2019, Volume 98, Issue 7, pp. 1713 - 1720
Symptomatic multiple myeloma (MM) is a plasma cell neoplasm that represents the final stage of a continuum of clinical conditions that start from monoclonal... 
LAG3 | Medicine & Public Health | Hematology | HLA-DR | Smoldering myeloma | PD-L1 | Oncology | Immune system | MULTIPLE-MYELOMA | CELLS | IMMUNOTHERAPY | IMMUNE CHECKPOINT | BLOCKADE | HEMATOLOGY | Medicine, Experimental | Medical research | T cells | Analysis | Multiple myeloma
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2005, Volume 23, Issue 23, pp. 5334 - 5346
Purpose To study the antiangiogenic effect of thalidomide. Patients and Methods The expression of key angiogenic genes was studied in bone marrow endothelial... 
KAPOSI-SARCOMA | THERAPY | ONCOLOGY | ANALOGS | SP1 | PROLIFERATION | GROWTH-FACTOR | NF-KAPPA-B | TRANSCRIPTIONAL REGULATION | EXPRESSION | CANCER | Sarcoma, Kaposi - metabolism | Humans | Middle Aged | Endothelium, Vascular - drug effects | Male | Paraproteinemias - genetics | Gene Expression Profiling | Vascular Endothelial Growth Factor A - metabolism | Thalidomide - pharmacology | Lymphoma, B-Cell - genetics | RNA, Messenger - metabolism | Vascular Endothelial Growth Factor A - genetics | RNA, Neoplasm - metabolism | Sarcoma, Kaposi - drug therapy | Multiple Myeloma - drug therapy | Aged, 80 and over | Fibroblast Growth Factor 2 - metabolism | Hepatocyte Growth Factor - genetics | Adult | Female | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Lymphoma, Large B-Cell, Diffuse - drug therapy | Paraproteinemias - drug therapy | Enzyme-Linked Immunosorbent Assay | Down-Regulation | Cells, Cultured | Angiogenesis Inhibitors - pharmacology | Multiple Myeloma - metabolism | Hepatocyte Growth Factor - metabolism | Culture Media, Conditioned | Fibroblast Growth Factor 2 - genetics | Endothelium, Vascular - metabolism | Paraproteinemias - metabolism | Bone Marrow - pathology | Endothelium, Vascular - pathology | Aged | Sarcoma, Kaposi - genetics | Multiple Myeloma - genetics | Umbilical Veins - metabolism
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 2987 - 2987
Abstract Background: The achievement of complete remission is an important therapeutic goal and prognostic factor for overall survival in patients with B-cell... 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2014, Volume 89, Issue 12, pp. 1085 - 1091
A subanalysis of the GIMEMA‐MMY‐3006 trial was performed to characterize treatment‐emergent peripheral neuropathy (PN) in patients randomized to... 
DEXAMETHASONE | CYCLOPHOSPHAMIDE | CONSOLIDATION THERAPY | REVERSIBILITY | POLYMERIZATION | PREDNISONE PLUS THALIDOMIDE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ELDERLY-PATIENTS | MELPHALAN | INDUCTION TREATMENT | Peripheral Nervous System Diseases - chemically induced | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Syndecan-1 - genetics | Gene Expression Regulation, Neoplastic | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Plasma Cells - pathology | Neurogenesis - genetics | Multiple Myeloma - drug therapy | Neoplasm Grading | Bone Marrow Transplantation | Adult | Female | Plasma Cells - metabolism | Peripheral Nervous System Diseases - pathology | Boronic Acids - administration & dosage | Peripheral Nervous System Diseases - genetics | Actin Cytoskeleton - genetics | Thalidomide - adverse effects | Peripheral Nervous System Diseases - mortality | Actin Cytoskeleton - metabolism | Bortezomib | Dexamethasone - administration & dosage | Syndecan-1 - metabolism | Antineoplastic Combined Chemotherapy Protocols | Axons - metabolism | Thalidomide - administration & dosage | Multiple Myeloma - pathology | Axons - pathology | Adolescent | Pyrazines - adverse effects | Survival Analysis | Aged | Drug Monitoring | Multiple Myeloma - genetics
Journal Article
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 10
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1990 - 1990
Abstract INTRODUCTION: Twice weekly carfilzomib is approved at two different doses, 27 mg/m2 in combination with lenalidomide and dexamethasone, and 56 mg/m2... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 2016 - 2016
Abstract The present study retrospectively analyzed a cohort of consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving allogeneic stem... 
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 08/2016, Volume 9, Issue 8, pp. 743 - 751
Journal Article